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Fibrodysplasia ossificans progressiva (FOP) [OMIM 135100] is a 
rare genetic disorder in which ossification of connective tissue leads 
to severe disability. It is an autosomal dominant trait and affected 
persons have mutations in the activin A type 1 receptor gene 
(ACVR1), chromosomal locus 2q23-24.1 ACVR1 is one of the f4 type 
1 receptors that mediate in the highly conserved bone morphogenetic 
protein (BMP) signalling pathway, through a domain rich in glycine 
and serine (GS-domain) residues.2,3
Diagnosing FOP has depended on recognising characteristic 
clinical and radiological features, and until recently the causative 
mechanism remained elusive.2,3 FOP molecular investigations 
has revealed that most affected individuals have the same single 
nucleotide change 617G>A in the ACVR1 gene. The base change 
is a missense mutation that leads to the substitution of arginine 
with histidine (R206H). The point mutation 617G>A in ACVR1 
that occurs in the GS-domain alters the ligand-dependent 
sensitivity for BMP signalling in connective tissue progenitor 
cells. Under normal circumstances, type 1 receptors such as 
ACVR1 are inactive until stimulated by extracellular BMPs 
through phosphorylation.1-3
FOP diagnosis is often delayed owing to its rarity. The clinical 
manifestations may also be confused with those of arthrogryposis 
multiplex congenita, several genetic rigid-joint syndromes, and 
various forms of childhood rheumatic disease.
As most genetic analyses have been carried out in white and Asian 
populations, the question arises as to whether or not this specific 
mutation (617G>A) is associated with FOP in all populations. No 
sub-Saharan black molecular studies interrogating the genetics of 
ACVR1/ALK2 and its association with FOP have been reported. 
Therefore, we investigated whether the commonly reported ACVR1/
ALK2 617G>A recurrent mutation also causes FOP in indigenous 
South Africans.
Methods
Six persons with FOP (4 Xhosa, 1 coloured and 1 white) were 
available for molecular investigation (Table 1). Three of them 
were the subject of reports, including full clinical and radiological 
descriptions, concerning the management and dental implications of 
FOP in South Africa.4,5
The main features of FOP in the affected South Africans were 
consistent with the literature. The severity and rate of progression 
are variable. FOP often presents at birth with shortening and 
deviation of the great toes. General health remains good and early 
development is normal. In mid-childhood, tender subcutaneous 
lumps may appear, frequently on the upper region of the back, 
that become ossified, and widespread ectopic ossification develops 
in the connective tissues. The limbs, neck and jaw become 
tethered by bands of ossification resulting in immobility. Finally, 
movements are limited to the external muscle of the eye and the 
diaphragm. Death usually occurs by middle age from respiratory 
insufficiency.
Blood was obtained for molecular genetic analysis from the 
6 FOP patients and 6 ethnic-matched controls after obtaining 
informed consent in accordance with the requirements of the Human 
Research Ethics Committee, University of Cape Town (ref HREC 
026/2010 – PB). Genomic DNA was extracted from peripheral 
blood leukocytes using a Qiagen DNA extraction kit (Valencia, 
USA). The single nucleotide polymorphism 617G>A in ACVR1 was 
analysed according to the method of Shore et al.1 using PCR and 
restriction fragment length polymorphism (RFLP) using HphI and 
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Objective. Fibrodysplasia ossificans progressiva (FOP) is a rare 
genetic condition in which progressive ossification of fibrous 
tissue, tendons and ligaments leads to severe physical handicap. 
Most affected individuals who have been studied have a recurrent 
617G>A mutation in the ACVR1/ALK2 gene that codes for activin 
A type 1 receptor/activin-like kinase 2. The majority of publications 
on the genetics of FOP have concerned whites or Asians, and no 
genetic information is available concerning sub-Saharan blacks. 
The aim of the project was to determine whether or not this 
mutation is present in affected persons in South Africa.
Method. Molecular mutational analysis was undertaken on 
genomic DNA from peripheral blood leukocytes from 6 affected 
South Africans of different population groups (4 Xhosa, 1 coloured, 
1 white).
Results. The 6 persons with FOP were all heterozygous for the 
ACVR1/ALK2 617G>A mutation. This mutation was absent in 6 
controls.
Conclusion. Confirmation of the presence of this recurrent 
mutation facilitates diagnostic accuracy in affected persons in 
South Africa, and allows researchers to narrow the search for 
molecular targets for rational intervention to the ACVR1/ALK2 
domain.
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Cac8I. The 617G>A mutation 
in ACVR1 eliminates a Cac8I 
site and forms a new HphI site 
(Fig. 1). In addition, each of 
the samples was subjected to 
sequence analysis.
Results
The 350 bp PCR product from 
the normal allele (617G) after 
digestion with Cac8I showed 
the 3 bands (139, 114, and 97 
bp) while the mutant allele 
(617A) appeared as 2 bands 
(253 and 97 bp) in persons 
with FOP. For HphI, PCR 
products of the 617G allele 
(normal) were not digested 
but PCR products of the 
617A allele showed bands of 
228 and 122 bp in the FOP 
patients. All 6 persons with 
FOP were heterozygous for 
the 617G>A mutation. The 
mutation was absent in all 
6 controls. Sequence analysis (Fig. 2) revealed the heterozygous 
genotype in all affected individuals while the controls had the normal 
homozygous 617G/G genotype.
Discussion
Most individuals with FOP are sporadic, representing new mutations 
for the determinant gene. Although FOP has a worldwide distribution, 
there are few previous reports of affected persons in South Africa.6 
Four of the 6 persons investigated in Cape Town are Xhosa. Reports 
from several other parts of the world have confirmed the presence 
of the 617G>A specific mutation in persons with FOP. However, 
the concept of 1 specific mutation in ACVR1 is no longer tenable 
as evidenced by the reports associating 605G>T, 983G>A, 774G>C 
and 1067G>A with FOP in the absence of the recurrent 617G>A.2,7 
Nevertheless, the important feature of these mutations is that their 
resulting amino acid changes mostly occur in the GS or kinase 
coding domains.7 This observation makes molecular sense in that 
different mutations in the ACVR1/ALK2 receptor gene could lead to 
different clinical manifestations of FOP. By extrapolation, mutations 
within the ACVR1/ALK2 receptor gene that cause variable ACVR1/
ALK2 receptor activity could also lead to different phenotypes, 
depending on the sensitivities of the domains in which they occur.2,7 
Table 1. Main features of the 6 subjects with FOP
Patient Gender Year of birth Ancestry Disability Additional comments
FOP
1.1
F 2005 Xhosa Extensive heterotopic ossification 
over back and spine. Arms and neck 
immobile and arms tethered to thorax.
Legs spared at this point.
FOP
2.1
M 1965 Xhosa Spine and arms completely immobile. 
Able to walk unaided.
No clinical features of thoracic 
insufficiency syndrome. Gainfully 
employed.
FOP
3.1
F 1964 Xhosa Completely immobile. Only able to 
move eyes and tongue.
Profound iron deficiency anaemia 
owing to diet of tea and bread as 
unable to open mouth and chew. 
Thoracic insufficiency syndrome and 
pulmonary hypertension.
FOP
4.1
F 2003 Coloured Heterotopic ossification over back and 
spine. Arms and neck immobile and 
arms tethered to thorax.
Presented after injury at school. Has 
had serious fall owing to inability to 
protect with arms and developed large 
swelling over right eye.
FOP
5.1
F 2009 Xhosa Hard mass between scapulae. Rigid 
cervical spine and limited abduction of 
arms.
Fitted with a helmet to protect against 
head injuries.
FOP
6.1
F 1997 White Spinal immobility noted only months 
before diagnosis.
Had surgical correction of toes at 5 
months of age.
Fig. 1. Mutation analysis of the ACVR1 in South African FOP patients. Patient samples were numbered 1.1; 2.1; 3.1 and 4.1, 
respectively. UD represents undigested 350 bp PCR product while MM is the molecular weight marker. Samples 18 and 40 
are healthy controls with no clinical manifestation of the disease. Each sample was digested with Hph I and Cac8 I in separate 
reactions and each reaction identified with either H for Hph I or C for Cac8 I respectively. The products for the separate diges-
tions for each enzyme were run alongside each other, for example, 1.1H and 1.1C, respectively. After Hph I digestion of the 
350 bp PCR product, the 617G allele (normal) was not digested but PCR products of the 617A allele showed bands of 228 and 
122 bp in the FOP patients only. The 350 bp PCR product from the normal allele (617G) after digestion with Cac8 I showed 
the three bands (139, 114, and 97 bp) while the mutant allele (617A) appeared as two bands (253 and 97 bp) in FOP patients.
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This concept could also argue for the involvement of mutations in 
ACVR1 receptor gene in other related disorders such as some forms 
of myositis.2,7
The identification of the recurrent 617G>A mutation in almost 
all FOP patients worldwide, together with the narrowing of all 
reported mutations to the GS and kinase domains of the ACVR1/
ALK2 gene, provides a specific target of intervention in a critical 
signalling pathway. The prime target in FOP would be inhibition of 
the BMP signalling pathway, using RNA technology or monoclonal 
antibodies.1,8 In South Africa, confirming the recurrent 617G>A 
mutation in all 6 patients suggests that genetic analysis can aid the 
diagnosis of suspected FOP, thereby negating the need for invasive 
procedures that can accelerate its progression.
Conclusions
Demonstrating that 6 affected South Africans with disparate 
antecedents have the same worldwide documented 617G>A mutation 
provides a firm starting point for establishing a diagnostic molecular 
testing facility for FOP in sub-Saharan Africa. In turn, awareness of 
FOP and the feasibility of molecular diagnostic confirmation would 
positively influence its medical management in Africa. The ubiquity 
of the 617G>A mutation could also facilitate research on identifying 
molecular intervention strategies that may be applied in FOP patients 
to slow the progression of the disorder, particularly by targeting the 
BMP signalling pathway.
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Fig. 2. DNA sequence analysis of a section of the ACVR1/ALK2 gene in South 
African FOP patients. The arrow indicates position of the gene where the 
mutation has been reported (c.617G>A; R206H). The numbering FOP1.1 to 
FOP6 refers to the different patients with GA representing the heterozygous 
genotype at this position.
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